James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 220,230 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total value of $744,377.40. Following the transaction, the chief executive officer now owns 3,194,583 shares in the company, valued at $10,797,690.54. This trade represents a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Checkpoint Therapeutics Stock Performance

CKPT stock opened at $3.75 on Monday. The firm has a 50 day moving average price of $3.59 and a 200-day moving average price of $2.72. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50. The firm has a market capitalization of $183.12 million, a price-to-earnings ratio of -2.04 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, sell-side analysts forecast that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Checkpoint Therapeutics

Several institutional investors have recently bought and sold shares of CKPT. PVG Asset Management Corp raised its holdings in Checkpoint Therapeutics by 9.2% in the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock worth $336,000 after buying an additional 12,676 shares during the last quarter. Virtu Financial LLC purchased a new position in Checkpoint Therapeutics in the 3rd quarter worth approximately $30,000. Geode Capital Management LLC lifted its position in Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares in the last quarter. State Street Corp boosted its stake in Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after purchasing an additional 23,000 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Checkpoint Therapeutics in the 3rd quarter worth $148,000. 22.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CKPT has been the topic of several research reports. Lake Street Capital lifted their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, December 16th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.